| 研究課題/領域番号 |
22KK0147
|
|---|
| 研究種目 |
国際共同研究加速基金(国際共同研究強化(B))
|
| 配分区分 | 基金 |
|---|
| 審査区分 |
中区分58:社会医学、看護学およびその関連分野
|
|---|
| 研究機関 | 長崎大学 |
|---|
研究代表者 |
吉田 レイミント 長崎大学, 熱帯医学研究所, 教授 (90432963)
|
|---|
| 研究分担者 |
樋泉 道子 長崎大学, 熱帯医学研究所, 准教授 (00778623)
柳原 克紀 長崎大学, 医歯薬学総合研究科(医学系), 教授 (40315239)
森内 浩幸 長崎大学, 医歯薬学総合研究科(医学系), 教授 (90315234)
|
|---|
| 研究期間 (年度) |
2022-10-07 – 2026-03-31
|
| 研究課題ステータス |
交付 (2024年度)
|
| 配分額 *注記 |
20,020千円 (直接経費: 15,400千円、間接経費: 4,620千円)
2024年度: 5,720千円 (直接経費: 4,400千円、間接経費: 1,320千円)
2023年度: 7,410千円 (直接経費: 5,700千円、間接経費: 1,710千円)
2022年度: 6,890千円 (直接経費: 5,300千円、間接経費: 1,590千円)
|
|---|
| キーワード | HBV / HDV / HCV / genotype / drug resistant / Nigeria / Genotype / Drug resistance / Hepatitis B Virus / Hepatitis C Virus / Hepatitis D Virus / incidence / drug resistant variant / Viral hepatitis / therapeutic |
|---|
| 研究開始時の研究の概要 |
DNA/RNA will be extracted from HBV and HCV positive serum samples stored at Nigeria CDC. PCR and sequencing will be performed to determine the genotype, drug resistant variants and predict optimal viral hepatitis therapeutic options. A rapid PCR based genotyping assays will be developed.
|
| 研究実績の概要 |
The main objective of the study was (i) to determine the patterns and prevalence of hepatitis B, C and D genotypes and circulating RAVs in Nigeria, and to predict the optimal VH therapeutic options for Nigeria. Upto now we have successfully processed and transported the DNA/RNA samples of hepatitis B, C and D samples for further testing to Nagasaki, Japan. We completed the HBV genotyping, drug resistant associated mutation analysis, and vaccine escape mutant analysis, and hepatitis D screening of the HBV positive samples. The study results has been published as Nigeria CDC PhD student's research paper (ref: Adewuyi O', et al. Molecular Epidemiology, Drug-Resistant Variants, and Therapeutic Implications of Hepatitis B Virus and Hepatitis D Virus Prevalence in Nigeria: A National Study. Pathogens. 2025 Jan 20;14(1):101). The Nigeria CDC PhD student graduated his PhD in 2025 March.
|
| 現在までの達成度 |
現在までの達成度
2: おおむね順調に進展している
理由
The study has been going on well but there was a delay is sample shipment from Nigeria to Nagasaki due to the COVID19 situation in Nigeria. Therefore, we have extended the study period to complete the genotyping and data analysis of HDV and HCV of the study. We aim to complete this in 2025 study period.
|
| 今後の研究の推進方策 |
We will conduct the whole genome sequencing experiment to determine the genotype, drug resistant variance of the HDV and HCV positive samples. The study results will be summarized (i) to presented at international meeting, and publication at peered reviewed journal.
|
